May 28, 2017
Recommended Topic Related To:


"Heart disease is the leading cause of death for both men and women, but heart disease is preventable and controllable.

Every journey begins with one step, whether it's climbing a mountain or preventing heart disease. This American Heart"...



How Supplied


NEXTERONE is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy. NEXTERONE also can be used to treat patients with VT/VF for whom oral amiodarone is indicated, but who are unable to take oral medication. During or after treatment with NEXTERONE, patients may be transferred to oral amiodarone therapy [see DOSAGE AND ADMINISTRATION].

Use NEXTERONE for acute treatment until the patient's ventricular arrhythmias are stabilized. Most patients will require this therapy for 48 to 96 hours, but NEXTERONE may be safely administered for longer periods if necessary.


Amiodarone shows considerable interindividual variation in response. Although a starting dose adequate to suppress life-threatening arrhythmias is needed, close monitoring with adjustment of dose is essential. The recommended starting dose of NEXTERONE is about 1000 mg over the first 24 hours of therapy, delivered by the following infusion regimen:


Loading infusions First Rapid: 150 mg over the FIRST 10 minutes (15 mg/min).
    Directly infuse NEXTERONE Premixed Injection (150 mg/100 mL; 1.5mg/mL) at a rate of 10mL/min.
  Followed by Slow: 360 mg over the NEXT 6 hours (1 mg/min). Directly infuse NEXTERONE Premixed Injection (360 mg/200 mL; 1.8 mg/mL) at a rate of 0.556 mL/min.
Maintenance infusion   540 mg over the REMAINING 18 hours (0.5 mg/min). Decrease the rate of the slow loading infusion to 0.5 mg/min. Directly infuse NEXTERONE Premixed Injection (360 mg/200 mL; 1.8 mg/mL) at a rate of 0.278 mL/min.

After the first 24 hours, continue the maintenance infusion rate of 0.5 mg/min (720 mg per 24 hours) by directly infusing NEXTERONE Premixed Injection (360 mg/200 mL; 1.8 mg/mL) at a rate of 0.278 mL/min. The rate of the maintenance infusion may be increased to achieve effective arrhythmia suppression.

In the event of breakthrough episodes of VF or hemodynamically unstable VT, use 150 mg supplemental infusions of NEXTERONE (infused over 10 minutes to minimize the potential for hypotension).

The first 24-hour dose may be individualized for each patient; however, in controlled clinical trials, mean daily doses above 2100 mg were associated with an increased risk of hypotension. Do not exceed an initial infusion rate of 30 mg/min.

Based on the experience from clinical studies of intravenous amiodarone, a maintenance infusion of up to 0.5 mg/min can be continued for 2 to 3 weeks regardless of the patient's age, renal function, or left ventricular function. There has been limited experience in patients receiving intravenous amiodarone for longer than 3 weeks.

Administer NEXTERONE, whenever possible, through a central venous catheter dedicated to that purpose. Use an in-line filter during administration.

Intravenous amiodarone loading infusions at much higher concentrations and rates of infusion much faster than recommended have resulted in hepatocellular necrosis and acute renal failure, leading to death [see WARNINGS AND PRECAUTIONS].

Intravenous amiodarone concentrations greater than 3 mg/mL have been associated with a high incidence of peripheral vein phlebitis; however, concentrations of 2.5 mg/mL or less appear to be less irritating. Therefore, for infusions longer than 1 hour, do not exceed NEXTERONE concentrations of 2 mg/mL, unless a central venous catheter is used [see ADVERSE REACTIONS].

NEXTERONE Premixed Injection is available in GALAXY containers as a single-use, ready-to-use, iso-osmotic solution in dextrose for intravenous administration. No further dilution is required. NEXTERONE Premixed Injection should not be combined with any product in the same intravenous line or premixed container. Do not add supplemental medication. Protect from light until ready to use.

NEXTERONE does not need to be protected from light during administration.

Since the premixed container is for single-use only, any unused portion should be discarded.

NOTE: Inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever solution and container permit, solution should be clear. Visually inspect the container. If the administration port protector is damaged, detached or not present, discard the container as the solution path sterility may be compromised. Check for minute leaks prior to use by squeezing the bag firmly. If leaks are detected, discard solution as sterility may be impaired.

CAUTION: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete.

Preparation of NEXTERONE Premixed Injection for administration:

  1. Suspend container from eyelet support.
  2. Remove protector from outlet port at bottom of container.
  3. Attach administration set. Refer to complete directions accompanying set.
Admixture Incompatibility

Amiodarone in D5W Injection forms precipitates with the drugs shown in Table 2. If coadministration of the following drugs is necessary, use separate intravenous administration lines.


Drug Vehicle Amiodarone Concentration
Aminophylline D5W; NS 4 mg/mL
Amoxicillin Sodium-Clavulanic Acid unknown 12.5 mg/mL
Ampicillin Sodium-Sulbactam Sodium NS 6 mg/mL
Argatroban D5W 1.8 mg/mL
Bivalirudin D5W 4 mg/mL
Cefamandole Nafate D5W 4 mg/mL
Cefazolin Sodium D5W 4 mg/mL
Ceftazidime D5W 6 mg/mL
Digoxin D5W 6 mg/mL
Furosemide (10 mg/mL) D5W 6 mg/mL
Mezlocillin Sodium D5W 4 mg/mL
Heparin Sodium D5W --
Imipenem-Cilastin Sodium D5W 6 mg/mL
Magnesium Sulfate (500 mg/mL) D5W 6 mg/mL
Micafungin NS 4 mg/mL
Piperacillin Sodium -Tazobactam Sodium D5W 6 mg/mL
Potassium Phosphates D5W 6 mg/mL
Sodium Bicarbonate D5W 3 mg/mL
Sodium Nitroprusside D5W 1.5, 6 and 15 mg/mL
Sodium Phosphates D5W 6 mg/mL
D5W = Dextrose 5% in Sterile Water, NS = Normal Saline

Intravenous to Oral Transition

Patients whose arrhythmias have been suppressed by NEXTERONE may be switched to oral amiodarone. The optimal dose for changing from intravenous to oral administration of amiodarone will depend on the dose of NEXTERONE already administered, as well as the bioavailability of oral amiodarone. When changing to oral amiodarone therapy, clinical monitoring is recommended, particularly for elderly patients. See package insert for oral amiodarone.

Since grapefruit juice is known to inhibit CYP3A-mediated metabolism of oral amiodarone in the intestinal mucosa, resulting in increased plasma levels of amiodarone, do not drink grapefruit juice during treatment with oral amiodarone [see DRUG INTERACTIONS].

Table 3 provides suggested doses of oral amiodarone to be initiated after varying durations of NEXTERONE administration. These recommendations are made on the basis of a similar total body amount of amiodarone delivered by the intravenous and oral routes, based on 50% bioavailability of oral amiodarone.


Duration of NEXTERONE Infusion# Initial Daily Dose of Oral Amiodarone
< 1 week 800-1600 mg
1-3 weeks 600-800 mg
> 3 weeks* 400 mg
# Assuming a 720 mg/day infusion (0.5 mg/min).
* NEXTERONE is not intended for maintenance treatment.


Dosage Forms And Strengths

Injection, 1.5 mg/mL (150 mg/100 mL) Premixed in Dextrose

Injection, 1.8 mg/mL (360 mg/200 mL) Premixed in Dextrose

Storage And Handling

NEXTERONE (amiodarone HCl) Premixed Injection is supplied as a ready-to-use, sterile, nonpyrogenic, iso-osmotic solution in 100 mL and 200 mL single-dose GALAXY containers (PL 2501 plastic) packaged in individual cartons as follows:

150 mg/100 mL NDC 43066 – 150 – 10 2G3451
360 mg/200 mL NDC 43066 – 360 – 20 2G3450

Do not add supplementary medication to NEXTERONE Premixed Injection. Store at 20° -25°C (68° -77°F); excursions permitted to 15° -30°C (59° -86°F). See USP Controlled Room Temperature. Protect from light and excessive heat. Protect from freezing. Use carton to protect contents from light until used.

Baxter Healthcare Corporation Deerfield, IL 60015. Revised: March 2015

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 12/5/2016

How Supplied

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Heart Health

Get the latest treatment options.

Atrial Fibrillation Quiz